 |
6 Diseases |  |
125 Trials |
|
125 Trials |  |
2571 News |  |
| «12...1314151617181920212223...3334» |
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Biomarker, Clinical, Review, Journal: Biomarkers of Trifluridine-Tipiracil Efficacy. (Pubmed Central) - Dec 13, 2021
These studies show that early neutropenia on treatment, and ratios of leukocyte subsets, are potential biomarkers able to predict trifluridine/tipiracil benefit. Combinations of laboratory values and clinical characteristics and proteins involved in trifluridine transport and activation have been examined with initial positive results.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Nivo-ipi. Never saw a Lonsurf response here. (Twitter) - Dec 13, 2021
- | CA102N / Holy Stone Healthcare
Trial primary completion date, Monotherapy, Metastases: First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 13, 2021
P1, N=33, Enrolling by invitation, Sponsor: Holy Stone Healthcare Co., Ltd
Combinations of laboratory values and clinical characteristics and proteins involved in trifluridine transport and activation have been examined with initial positive results. Trial primary completion date: Sep 2021 --> Dec 2021
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Erbitux (cetuximab) / Eli Lilly
New P1 trial, Combination therapy, Metastases: Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC (clinicaltrials.gov) - Dec 12, 2021
P1, N=6, Recruiting, Sponsor: Wuhan Union Hospital, China
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Retrospective data, Review, Monotherapy: A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Dec 7, 2021
Bevacizumab combined with TAS-102 could improve the prognosis of patients with mCRC who have failed standard treatment. In terms of side effects, the addition of bevacizumab did not increase serious adverse reactions, but the occurrence of thrombocytopenia was worth noting.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Dec 6, 2021
P3, N=434, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
In terms of side effects, the addition of bevacizumab did not increase serious adverse reactions, but the occurrence of thrombocytopenia was worth noting. Recruiting --> Active, not recruiting
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, UCB6114 / UCB
A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_612;
P1/2
Enrollment in ONC001 began in July 2020; as of Sept 2021, four dose escalation levels in the monotherapy dose-escalation module (Part A) have been completed without DLT. Recruitment to parts B and C is due to commence in Q4 2021.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, VS-6766 / Verastem
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC). (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_610;
Regorafenib or TAS-102 is commonly used however, the modest clinical benefit, and toxicity limit their use...Adagrasib (a KRAS G12C inhibitor) was used with/without cetuximab in heavily pretreated CRC pts harboring KRAS G12C mts...Phase 1b CodeBreaK101 study evaluating sotorasib (KRAS G12C inhibitor) and panitumumab (anti-EGFR) combination in KRAS G12C mt CRC showed 15.4% confirmed ORR and 26.9% unconfirmed ORR...Eligible pts include those with metastatic CRC and progression after 5-FU, oxaliplatin, irinotecan and VEGFi therapy...The study is funded by research grants from Verastem Oncology. Cetuximab will be supplied by Eli Lilly.
- Tecentriq (atezolizumab) / Roche, Reolysin (pelareorep) / Oncolytics, Andrus Reo
GOBLET: A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab. (In-Person Only | Level 1, West Hall; Poster Board - Q1) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_608;
The primary objectives are safety and efficacy based on objective response rate (ORR) at week 16. Any cohort showing a promising ORR in Stage 1, based on pre-specified criteria, may be advanced to Stage 2 and enroll additional patients.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress). (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_607;
P3
This trial is actively accruing across 39 institutions in Japan and Taiwan and opened to recruitment in August 2018. By October 2021, a total of 67 patients have been enrolled.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC). (In-Person & On Demand | Level 1, West Hall; Poster Board - F4) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_511;
P2
B+P did not significantly improve median PFS or OS compared to TAS-102 in KRAS/NRAS mut mCRC. Subgroup analyses and translational studies are ongoing to determine which subgroups may be more likely to attain 4-mo PFS or identify mechanisms of resistance.
- Elunate (fruquintinib) / Hutchmed
Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer. (In-Person & On Demand | Level 1, West Hall; Poster Board - E5) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_488;
P1, P3
Evidence of antitumor activity was observed in cohorts B and C. The multi-cohort dose expansion is ongoing. F is being further investigated in refractory mCRC in a global Ph 3 study (NCT04322539).
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Avastin (bevacizumab) / Roche
Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer. (In-Person & On Demand | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_483;
Pts with histologically confirmed mCRC who failed first-line chemotherapy with fluoropyrimidine and oxaliplatin plus either BEV or an anti-EGFR antibody were eligible... FTD/TPI + BEV might be a second-line treatment option for mCRC pts with low tumor burden (STL < 60 mm).
- irinotecan / Generic mfg.
Treatment patterns and outcomes of patients with metastatic colorectal cancer in third-line and beyond systemic therapy: Real-world data from a setting with limited resources. (In-Person & On Demand | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_455;
Rechallenge with chemotherapy and anti-EGFR agents is overused in a setting of limited access to therapies with demonstrated OS benefit, such as regorafenib and TAS-102. Barriers to drug access impair the adoption of the best evidence-based continuum of care and strategies to overcome them are urgently needed.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Real-world persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with colorectal cancer. (In-Person & On Demand | Level 1, West Hall; Poster Board - C3) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_446;
Results of this real-world study suggest that patients with CRC initiating FTD/TPI have improved adherence and persistence with therapy compared with those initiating regorafenib. Reasons for this difference and potential impacts on health outcomes require further study.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Vitrakvi (larotrectinib) / Bayer, Stivarga (regorafenib) / Bayer
The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer. (In-Person & On Demand | Level 1, West Hall; Poster Board - B9) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_438;
P1, P1/2,
In metastatic CRC, larotrectinib may produce substantial life expectancy and quality-adjusted life-year gains compared to regorafenib or trifluridine/tipiracil. Additional data with longer follow-up times will further inform this comparison.
- Rozlytrek (entrectinib) / Roche, Vitrakvi (larotrectinib) / Bayer
The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer. (In-Person & On Demand | Level 1, West Hall; Poster Board - B8) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_437;
P1, P1/2,
In metastatic TRK fusion CRC, larotrectinib may produce substantial life expectancy and quality-adjusted life-year gains compared to entrectinib. Additional data with longer follow-up times will further inform this comparison.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
A real-world comparison of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer in the United States. (In-Person & On Demand | Level 1, West Hall; Poster Board - B7) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_436;
Median OS with both agents in a real-world setting was similar to that shown in the clinical trials that led to their approvals. This data should be considered when discussing the risks and benefits of TAS-102 and regorafenib with mCRC patients who are eligible for third line or greater treatment.
- Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC). (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_177;
P3
Primary endpoint: OS. Secondary endpoints: PFS, response rate, quality of life, toxicity, exploratory correlative biomarkers.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors. (Live Stream | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_162;
P1
The clinical benefit was observed in pts at different dose levels. The expansion portion of the study is still ongoing and pts will be followed until disease progression or consent withdrawal.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Cyramza (ramucirumab) / Eli Lilly
A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs). (Live Stream | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_91;
P2
The combination has now shown modest activity in advanced GEAs and should be investigated further now in the context of patients receiving immunotherapy-based treatment as first-line treatment. A randomized phase II study is currently enrolling patients with ramucirumab and TAS-102 or paclitaxel.
- Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Effectiveness of third- or later-line therapy in patients with HER2-positive advanced gastric cancer: Results from an observational retrospective study in Japan. (Live Stream | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_66;
The real-world effectiveness of 3L+ therapies was limited in this study. New HER2 treatment agent is expected to improve outcomes in pts with HER2-positive G/GEJ cancer.CI, confidence interval; OS, overall survival; PFS, real-world progression-free survival; TTF, time to treatment failure.
- Opdivo (nivolumab) / Ono Pharma, BMS
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC). (Live Stream | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_46;
CTx consisted of irinotecan alone (IRI), trifluridine/tipiracil alone (FT), and oxaliplatin-containing regimens (OX). Prior NIVO therapy may lead to improved prognosis after CTx without unexpected AEs in pts with AGC, warranting further investigations after NIVO is approved as first-line treatment.
- || irinotecan / Generic mfg.
Retrospective data, Review, Journal: Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer. (Pubmed Central) - Dec 1, 2021
Regorafenib (80 mg) was superior to the placebo, but inferior to 160 mg regorafenib, trifluridine/tipiracil, and fruquintinib. This study further revealed that the efficiency of trifluridine/tipiracil and fruquintinib is identical, but their toxicity profiles are different.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal: Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. (Pubmed Central) - Dec 1, 2021
The Quality of Life Questionnaire Core 30 score improved in 25.4% of the patients. Safety, efficacy and quality of life results confirmed trifluridine/tipiracil as a feasible and favorable treatment option for metastatic colorectal cancer patients.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Opdivo (nivolumab) / Ono Pharma, BMS
Journal, HEOR: Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. (Pubmed Central) - Nov 29, 2021
Safety, efficacy and quality of life results confirmed trifluridine/tipiracil as a feasible and favorable treatment option for metastatic colorectal cancer patients. Trifluridine/tipiracil was more cost-effective than nivolumab for patients with heavily pretreated metastatic gastric cancer.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Retrospective data, Journal: Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study. (Pubmed Central) - Nov 24, 2021
Our findings indicate that it might be better to prescribe TFTD first. Furthermore, owing to the longer OS than monotherapy, sequential administration of regorafenib and TFTD ought to be considered.
- ||| ASP1570 / Astellas
Enrollment open, Trial completion date, Trial primary completion date, Monotherapy: KEYNOTE-E59: A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors (clinicaltrials.gov) - Nov 24, 2021
P1, N=138, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Furthermore, owing to the longer OS than monotherapy, sequential administration of regorafenib and TFTD ought to be considered. Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> May 2024 | Trial primary completion date: Aug 2023 --> May 2024
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Metastases: TACTIC: Trifluridin/tipirACil in meTastatIc Colorectal Cancer (clinicaltrials.gov) - Nov 22, 2021
P=N/A, N=315, Completed, Sponsor: Servier Deutschland GmbH
Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> May 2024 | Trial primary completion date: Aug 2023 --> May 2024 Active, not recruiting --> Completed
- | Lonsurf (trifluridine/tipiracil) / Otsuka, PolyPEPI 1018 / Treos Bio
New P1 trial, Metastases: OBERTO-201: A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 21, 2021
P1, N=15, Not yet recruiting, Sponsor: Mayo Clinic
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Biomarker, Clinical, P2 data, Journal: Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers. (Pubmed Central) - Nov 21, 2021
The current phase II trial demonstrated that trifluridine/tipiracil was an effective and well-tolerated option for elderly patients with advanced colorectal cancer. Moreover, geriatric assessment tools and/or plasma drug concentration monitoring might be helpful in predicting the efficacy and toxicities in elderly patients receiving this drug.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, PK/PD data, Journal: A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. (Pubmed Central) - Nov 21, 2021
P1
Moreover, geriatric assessment tools and/or plasma drug concentration monitoring might be helpful in predicting the efficacy and toxicities in elderly patients receiving this drug. FTD/TPI is safe and tolerable at the recommended 35 mg/m dose in patients with mild/moderate RI and at the reduced 20 mg/m dose in patients with severe RI.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Optimal treatment for metastatic gastric cancer: The new role of TAS-102 (Room D [VIRTUAL]) - Nov 20, 2021 - Abstract #KSMO2021KSMO_48;
FTD/TPI is safe and tolerable at the recommended 35 mg/m dose in patients with mild/moderate RI and at the reduced 20 mg/m dose in patients with severe RI. Sponsored by JEIL
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Optimal treatment for metastatic colorectal cancer: The new role of TAS-102 (Room D [VIRTUAL]) - Nov 20, 2021 - Abstract #KSMO2021KSMO_47;
Sponsored by JEIL Sponsored by JEIL
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
TAS-102, New therapeutic option for patients with CRC / GC (Room D [VIRTUAL]) - Nov 20, 2021 - Abstract #KSMO2021KSMO_46;
Sponsored by JEIL Sponsored by JEIL
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal: Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil. (Pubmed Central) - Nov 17, 2021
In the multivariate analysis, reduced OS was found in patients with ≥5% SML (HR: 2.03 (1.11-3.72), p = 0.0039). We describe the prognostic role of sarcopenia beyond second line treatment and analyze other factors, such as performance status, tumor histological differentiation or carcinoembryonic antigen level that could predict TT treatment response.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
P1 data, Journal: A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. (Pubmed Central) - Nov 17, 2021
TAS-OX is safe with no unexpected toxicities at standard doses of each agent. The combination did not result in a clinically meaningful ORR, although progression-free survival and overall survival were encouraging in this heavily pretreated population.
- Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Trial completion date, Metastases: TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) (clinicaltrials.gov) - Nov 16, 2021
P2, N=4, Completed, Sponsor: University of Florida
The combination did not result in a clinically meaningful ORR, although progression-free survival and overall survival were encouraging in this heavily pretreated population. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Aug 2021
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] An Open-Label, Phase II Investigation of Trifluridine/Tipiracil in Patients With HighGrade, Extrapulmonary Neuroendocrine () - Nov 15, 2021 - Abstract #NANETS2021NANETS_93;
While one patient did experience prolonged stable disease, the study was halted due to pre-specified metrics of inactivity. FTD/TPI was not found to be effective in the second-line setting for high-grade, extrapulmonary neuroendocrine carcinoma.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal: Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. (Pubmed Central) - Nov 10, 2021
Several topics were dealt with, covering the profile of eligible patients, therapeutic options beyond the second line, the practice of treatment with FTD/TPI, evaluation and efficacy and toxicity, as well as costs and compliance. FTD/TPI is an important therapeutic resource in refractory metastatic colorectal cancer that combines manageability and safety.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Retrospective data, Review: Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. (Pubmed Central) - Nov 10, 2021
Pembrolizumab was more likely to cause immune related adverse event...Apatinib and nivolumab are the most effective treatments for the third-line treatment of AGC in contrast to the third-line chemotherapy. For AGC patients with HER-2 positive tumor, patients with GEJ cancer and patients without gastrectomy history, ICIs could be the optimal third-line treatment choice.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] LONSURF (trifluridine and tipiracil) tablets: Oral chemotherapy for previously treated metastatic colorectal, gastric and gastroesophageal (GEJ) cancers () - Nov 7, 2021 - Abstract #GDUGI2021GDU_GI_374;
For AGC patients with HER-2 positive tumor, patients with GEJ cancer and patients without gastrectomy history, ICIs could be the optimal third-line treatment choice. Presented by Taiho Oncology, Inc
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal, Real-world evidence: Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. (Pubmed Central) - Nov 7, 2021
TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series.
- |||||| Keytruda (pembrolizumab) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment open, Metastases: KEYFORM-007: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) (clinicaltrials.gov) - Nov 2, 2021
P3, N=432, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series. Not yet recruiting --> Recruiting
- |||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Clinical: I was impressed by the recent randomized controlled trial of CAPE+BEV 🆚 TAS-102+BEV Rather than just a dose reduction, ➡️ more of a 💡maintenance/single-agent approach as opposed to doublets+biologics. Was at @ASCO @ASCO_pubs #GI21 TASCO-1 #Clinicaltrials #CRCSM #GeriOnc (Twitter) - Nov 2, 2021
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Enrollment change, Combination therapy, Metastases: Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (clinicaltrials.gov) - Nov 2, 2021
P1, N=18, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=33 --> 18
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
Enrollment closed: TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Nov 1, 2021
P2, N=23, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | N=33 --> 18 Recruiting --> Active, not recruiting
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy: TRITICC: Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma (clinicaltrials.gov) - Nov 1, 2021
P2, N=28, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Apr 2024 | Trial primary completion date: Feb 2022 --> Oct 2023
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal: Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. (Pubmed Central) - Oct 31, 2021
Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Apr 2024 | Trial primary completion date: Feb 2022 --> Oct 2023 FTD/TPI plus bevacizumab showed promising activity with an acceptable safety profile for pretreated mCRC, regardless of RAS mutation status, although the efficacy outcomes tended to be better in RAS WT.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer. (Pubmed Central) - Oct 31, 2021
Our findings suggest that NIVO treatment is a more favorable option for patients with slow-growing tumors, and NIVO and IRI are similarly recommended for patients with rapid-growing tumors in refractory AGC. TGR and NL emergence during preceding treatment may be helpful for drug selection and warrant further investigation.